-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-103 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GM-103 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GM-103 in Metastatic Renal Cell Carcinoma Drug Details: GM-103...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-60106 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GM-60106 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GM-60106 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: GM-60106...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-6 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GM-6 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GM-6 in Parkinson's Disease Drug Details: GM-6 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bria-IMT in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Triple-Negative Breast Cancer (TNBC) Drug Details: Bria-IMT...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bria-IMT in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT in Metastatic Breast Cancer Drug Details: Bria-IMT (BriaVax) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bria-IMT in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bria-IMT in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bria-IMT in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bria-IMT...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Molgramostim in Mycobacterium Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Molgramostim in Mycobacterium Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Molgramostim in Mycobacterium Infections Drug Details: Molgramostim (Molgradex) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Molgramostim in Lung Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Molgramostim in Lung Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Molgramostim in Lung Disease Drug Details: Molgramostim (Molgradex) is under development...
-
Thematic Analysis
NewCybersecurity in Automotive – Thematic Intelligence
Cybersecurity in Automotive Thematic Report Overview Cybersecurity is crucial for all automotive businesses to prevent hackers from compromising the safety and advanced driver assistance systems (ADAS) of a vehicle in use or, worse, manipulating any autonomous functionality to directly cause a crash. At a higher level, automotive companies are also at risk of industrial cybercrime, such as the theft of valuable tech secrets or damage to their digital infrastructure. The ‘Cybersecurity in Automotive’ thematic intelligence report provides insights into the...